Cathay Pacific joins Pharma.Aero
Membership of the pharma supply chain association recognises the airline’s capabilities in handling high-value, time-sensitive pharmaceutical products
Cathay Pacific has become a full member of Pharma.Aero, a cross-industry collaboration for pharma shippers, CEIV-certified cargo communities, airport operators and other air cargo industry stakeholders. Cathay Pacific has been CEIV Pharma certified since October 2017.
Pharma.Aero, whose aim is to achieve excellence in the reliable, end-to-end air transportation and handling of high-value, time-sensitive pharmaceutical products, announced Cathay Pacific’s membership today at the IATA World Cargo Symposium in Singapore.
Cathay Pacific Regional Head of Cargo for South Asia, Middle East and Africa said – Rajesh Menon said: “India and Bangladesh are both big markets for Cathay Pacific, especially when it comes to shipments of pharmaceutical products. Hyderabad, Bangalore and Mumbai followed by Dhaka have always had large number of pharma shipments and this continues to grow. United States, Canada and Australia are key trade lanes for India and Bangladesh. PharmaLIFT is an important product and our handling expertise is a key USP we provide to our agents. Collaborating with Pharma.Aero, this offering will only become stronger to provide quality in the transportation and expert handling of valuable and sensitive pharmaceutical products”
Pharmaceutical shipments travelling the corridor will be handled in strict compliance with the IATA’s CEIV Pharma standard. Shippers will be assured of seamless airport-to-airport (A2A) temperature-controlled handling, assuring the integrity of the shipments.
Nathan De Valck, Chairman of Pharma.Aero added: “We are excited about Cathay Pacific joining our collaboration group as a full member. Their active involvement in the pilot of the pharma corridor project is a clear added value. In collaboration with Pharma.Aero and our pharma shipper members, key performance indicators of the pharma corridor will be clearly defined, targeting to set A2A pharma handling standards.”
